Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Molecular targeting to treat gastric cancer
Keishiro Aoyagi, Kikuo Kouhuji, Junya Kizaki, Taro Isobe, Kousuke Hashimoto, Kazuo Shirouzu, Department of Surgery, Kurume University School of Medicine, Fukuoka 830-0011, Japan
Author contributions: Aoyagi K contributed to management of the research, responsible for writing and revising the full text this review article; Kizaki J, Isobe T and Hashimoto K contributed to analysis of data and clinical work; all authors revised this paper finally.
Correspondence to: Keishiro Aoyagi, MD, PhD, Department of Surgery, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan. keishiro@med.kurume-u.ac.jp
Telephone: +81-942-353311 Fax: +81-942-340709
Received: October 27, 2013
Revised: January 13, 2014
Accepted: May 23, 2014
Published online: October 14, 2014
Processing time: 353 Days and 21.9 Hours
Revised: January 13, 2014
Accepted: May 23, 2014
Published online: October 14, 2014
Processing time: 353 Days and 21.9 Hours
Core Tip
Core tip: So far, trastuzumab is the only molecular targeting therapy that has been approved for treating gastric cancer. The significance of molecular targeting therapy for gastric cancer remains controversial, but large scale randomized clinical trials might confirm the benefits of other novel molecular targeting therapies for gastric cancer in the near future.